News - Neocirculation


The NEO-CIRC project started on the 1st October 2011.
Saturday, October 1, 2011
Brighton and Sussex University Hospitals are leading an international team of 18 partners that have been granted 6m EUR (approx. £5.1m) to investigate and improve circulation in newborn babies.

The study, entitled ‘Neocirculation’, will focus on the use of the drug dobutamine for the treatment of circulatory failure in the first two days after birth, where sustained low blood pressure and impaired blood flow to organs can cause brain injury resulting in poor neurodevelopmental outcomes. Neurodevelopmental disorders are associated with mental, emotional and physical disorders of varying severity. There is strong evidence that the use of dobutamine will reduce the incidence of these disabilities.

This project will produce data to define the use of dobutamine and clinical practice in both full term and premature infants when dealing with circulatory failure. The project will involve the development of a biobank of maternal and infant DNA so that the genetic factors related to the success of the response of infants to the drug can be analysed.

The five year project funded by the European Commission, under the FP7 programme, and coordinated by Brighton and Sussex University Hospitals involves 18 partners from 8 countries, including world-leading experts from eight universities spread throughout Europe, in addition to research institutes, hospitals and SME’s. The consortium also includes US American partner- Tufts Medical Center, based in Boston.

PD Dr Heike Rabe, Consultant Neonatalologist at the Brighton and Sussex University Hospitals says “This project will help doctors to treat their sickest babies earlier and better in the future. ” The NEO-CIRC project started on the 1st October 2011.